Michelle Keefe - Feb 23, 2023 Form 4 Insider Report for Syneos Health, Inc. (SYNH)

Role
Chief Executive Officer, Director
Signature
/s/ Sara Epstein, Attorney-in-Fact
Stock symbol
SYNH
Transactions as of
Feb 23, 2023
Transactions value $
-$127,679
Form type
4
Date filed
2/24/2023, 04:05 PM
Previous filing
Jan 19, 2023
Next filing
May 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYNH Class A Common Stock Award $0 +4.63K +2.42% $0.00 195K Feb 23, 2023 Direct F1
transaction SYNH Class A Common Stock Award $0 +1.2K +0.62% $0.00 197K Feb 23, 2023 Direct F2
transaction SYNH Class A Common Stock Award $0 +3.37K +1.71% $0.00 200K Feb 23, 2023 Direct F3
transaction SYNH Class A Common Stock Tax liability -$128K -3.34K -1.67% $38.25 197K Feb 23, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2022.
F2 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2022 and will vest in full on the date on which the Compensation and Management Development Committee (the "Committee") of the Board of Directors of Syneos Health, Inc. (the "Issuer") determines the attainment level of the performance goals for the year ended December 31, 2023, subject to continued employment.
F3 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2022 and will vest in full once the Committee determines the attainment level of the performance goals for the year ended December 31, 2024, subject to continued employment.